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Mesenchymal stromal cells (MSCs) are heterogeneous and primitive cells discovered first in the bonemarrow
(BM). They have putative roles in maintaining tissue homeostasis and are increasingly recognized as compo-
nents of stem cell niches, which are best defined in the blood. The absence of in vivoMSCmarkers has limited
our ability to track their behavior in vivo and draw comparisons with in vitro observations. Here we review the
historical background of BM-MSCs, advances made in their prospective isolation, their developmental origin
and contribution to maintaining subsets of hematopoietic cells, and how mesenchymal cells contribute to
other stem cell niches.Introduction
Adult stem cells emerge during development and are character-
ized by loss of pluripotency and a differentiation ability that is
tissue restricted. The existence of such cells was first demon-
strated in the hematopoietic system with the seminal work of
Till and McCulloch showing that cells from the BM can give
rise to multilineage descendants while retaining the ability to
self-renew (McCulloch and Till, 1960; Siminovitch et al., 1963;
Till and McCulloch, 1961). The same tissue was subsequently
shown to contain a different population of multipotent cells
through the work of Friedenstein and colleagues, who demon-
strated that the rodent bone marrow (BM) contains cells that
have the ability to form fibroblastoid colonies (CFU-F) when
cultured on plastic, make bone, and reconstitute the hematopoi-
etic microenvironment when transplanted subcutaneously (Frie-
denstein et al., 1968, 1970, 1976, 1982)
The ready ability to culture the cells and differentiate them into
different mesenchymal lineages in vitro made these cells the
subject of intensive investigation for their potential use in regen-
erative medicine and tissue engineering.
Cells having CFU-F and multi-lineage in vitro differentiation
capacity were demonstrated to be present in many tissues other
than the BM such as adipose tissue, umbilical cord, placenta,
amniotic fluid, dental pulp, skeletal muscle, tendons, and syno-
vial membrane (reviewed by Via et al., 2012). This created an ex-
plosion of interest and a tendency to conflate a similarity of
in vitro characteristics with identical in vivo biology. However,
what is emerging is a more nuanced understanding of distinct
subsets of MSCs, which is likely just the beginning of a complex
network of stromal components with interrelated and comple-
mentary in vivo capabilities.
Historical Background
The idea that a non-hematopoietic, mesenchymal stem cell pop-
ulation exists in the BM dates back to the nineteenth century
through the work of the German pathologist Cohnheim. He
hypothesized that fibroblastic cells participating in injury repair
come from the BM (Prockop, 1997). Later, in the early twentieth
century, and as an essential part of the ‘‘unitarian theory of hem-
atopoeisis,’’ the Russian scientist Alexander Maximov proposedthat committed blood cells descend from a hematopoietic stem
cell through signals from BM stromal cells (Friedenstein, 1989).
Suggestive experimental evidence emerged more than half a
century later when Friedenstein detected bone of donor origin
in semi-syngeneic BM-transplanted animals consistent with
marrow-providing cells that can generate non-hematopoietic,
mesenchymal tissue (Friedenstein et al., 1968). Similar observa-
tions were made by Tavassoli and Crosby (1968) when they
reported that autologous bone fragments survived after trans-
plantation in extramedullary sites due to reticular cells that prolif-
erated and gave rise to osteoblasts and trabecular bone with
a complete reconstitution of the hematopoietic and adventitial
structures. In parallel, the in vivo tracing of bone cells was being
made possible through the use of autoradiograpy in a series of
publications by Owen and colleagues, where the authors made
a surprising observation at the time that bone cells in the inner
periosteal surface proliferate, and these were termed pre-osteo-
blasts (Owen, 1963, 1967; Owen and MacPherson, 1963). When
similar cells were detected in human BM aspirates (Castro-
Malaspina et al., 1980; Gartner and Kaplan, 1980) and shown
capable of differentiating into osteogenic, adipogenic, chondro-
genic, and myogenic mesenchymal lineages in vitro (Beresford
et al., 1992; Friedenstein et al., 1987; Howlett et al., 1986; Mar-
don et al., 1987; Owen and Friedenstein, 1988; Pittenger et al.,
1999; Wakitani et al., 1995), they were termed ‘‘mesenchymal
stem cells’’ (as coined by Caplan, 1991). The potential for the
cells to be stem cells was evident, but it would now be required
to formally demonstrate self-renewal and differentiation in vivo to
apply the ‘‘stem cell’’ label. In fact, the first bone formation in vivo
by single-colony-derived humanBMMSCswasn’t demonstrated
until the late nineties, where immunodeficient mice were used
and where hematopoietic tissue was also detected in the trans-
plants (Kuznetsov et al., 1997). It is for that reason that we refer to
the mesenchymal stem cell as mesenchymal stromal cell (MSC).
Some of the cells so designated are true stem cells, but much of
the literature about them involves cells not formally tested for
stemness.
Given that adherent mesenchymal cells participated in sup-
port of hematopoietic cells in vitro (Dexter et al., 1977; GartnerCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 239
Figure 1. A Timeline Representation of Major Discoveries that Shaped Our Understanding of MSCs and the Hematopoietic
Microenvironment
The work of 19th and 20th century scientists such as Conheim and Maximov shaped the early hypothesis concerning the existence of a BM stem
cell population that is different from the HSC and that might be involved in its regulation. The concept was subsequently refined by Schofield who hy-
pothesized that the microenvironment in which HSCs reside regulates and preserves their activity. The existence of MSCs was proven through the work
of Friedenstein, which was crucial in the development of long-term HSC culture protocols. It was only in the dawn of the 21st century that the existence of
the hematopoietic microenvironment was independently demonstrated in vivo through the work of Calvi and Zhang. Since then, technological advances
at the level of genetically engineered animals in addition to cell labeling and sorting are expanding our understanding of MSC phenotypic and functional
heterogeneity.
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and contradicting data emerged regarding their role in BM trans-
plants based on the hypothesis that theymight be transplantable
themselves (Bentley et al., 1982; Dexter, 1982; Keating et al.,
1982). Studies were highly variable in terms of the pre-transplant
conditioning protocols and the heterogeneous and ambiguous
nature of the MSC cultures. Moreover, the ‘‘mesenchymal
stem cell’’ nomenclature proved to be problematic when it
became obvious that not all the plastic adherent stromal cells
have comparable self-renewal and in vivo differentiation ability
into multiple lineages (Horwitz and Keating, 2000). This led the
International Society for Cellular Therapy (ISCT) to issue a
nomenclature clarification restricting the use of the term Mesen-
chymal Stem Cells for cells that meet the stem cell criteria and
recommending the termMultipotentMesenchymal Stromal Cells
for the fibroblast-like plastic adherent cells regardless of the
tissue of origin. This clarification kept the widely recognized
acronym (MSC) in use (Horwitz et al., 2005). A year later, ISCT
issued the minimal criteria for defining MSCs. This required
adherence to plastic under standard culture conditions; the
expression of CD105, CD73, and CD90; the lack of expression
of CD45, CD34, CD14 or CD11b, and CD79a or CD19; and
HLA-DR surface molecules in addition to the ability to differen-
tiate into the osteogenic, chondrogenic, and adipogenic lineages
in vitro (Dominici et al., 2006). See Figure 1 for major discoveries
that shaped our understanding of MSCs and the hematopoietic
microenvironment.
Nearly a decade later, the ISCT criteria have not fully resolved
the complexity and heterogeneity of MSC preparations. Our un-
derstanding of the function of the different subsets and their
contribution to tissue homeostasis and regeneration in vivo re-
mains limited. Focusing definitions on cell features in vitro has
unfortunately not helped resolve features of the cell in vivo and
may be misleading, since there is evidence of a marked global240 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.gene expression difference depending on whether the cells are
freshly isolated or cultured (Churchman et al., 2012; Harichan-
dan et al., 2013). The expression of cell surface molecules
such as low-affinity nerve growth factor receptor (LNGFR), also
known as CD271, and the melanoma cell adhesion molecule
(MCAM), also known as CD146, both of which have been
described to label uncultured multipotent MSCs (Mabuchi
et al., 2013; Sacchetti et al., 2007; Tormin et al., 2011) are altered
when the cells are cultured. In the case of CD271, its expression
is lost when cultured in media containing bFGF (Quirici et al.,
2002). Similarly, CD146 expression is upregulated once the cells
are cultured and downregulated when cultured under hypoxic
conditions (Tormin et al., 2011). Also, CD44, which is expressed
by mouse and human cultured MSCs, does not label uncultured
MSCs (Qian et al., 2012). There is also evidence that culturing
conditions might be selecting for certain clones with specific
characteristics. Oxygen levels for example seem to be a critical
factor for culturing murine MSCs. Whereas atmospheric oxygen
levels inhibit the growth and differentiation of murine BM MSCs
through a p53-dependent mechanism, low oxygen levels had
the opposite effect (Boregowda et al., 2012). Moreover, the trili-
neage differentiation in culture doesn’t seem to faithfully reflect
the multipotency of the same cells in vivo. While MSCs labeled
by inducible Myxovirus Resistance-1 (Mx-1) promoter Cre in
the murine BM satisfied the requirement of trilineage differentia-
tion in vitro, they showed a limited lineage potential in vivo, label-
ing less than 5% of adipocytes in the BM with no labeling
detected in chondrogenic tissue even with tissue injury (Park
et al., 2012). These cells were capable of providing long-term
replenishment of osteoblasts, and freshly isolated cells were
transplantable. They are therefore likely to represent a lineage-
restricted bone stem cell. However, these studies made clear
that the in vitro features of MSC are not indicative of in vivo
function.
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Monoclonal antibodies (Ab) and flow cytometry have long been
used to identify MSCs without resorting to cell culture. In human
cells, CD271 was tested after it was shown to label cells from all
three germ layers, including non-neural cell types (Thomson
et al., 1988). Subsequently, CD271 was found to label stromal
cells in human BM and in the fetal BM even before the appear-
ance of hematopoietic activity (Cattoretti et al., 1993). A decade
later, CD271 was shown to enrich for CFU-F in the human BM
alone or in combination with other cell surface markers (Jones
et al., 2010; Jones et al., 2006; Quirici et al., 2002).
In an elegant study by the group of Paolo Bianco, another cell
surface molecule, CD146, was shown to label BM adventitial
reticular cells that were enriched for CFU-Fs and were able to
transfer hematopoietic support in the form of heterotopic ossi-
cles in immuno-compromised mice. Interestingly, when har-
vested and subjected to enzymatic dissociation, these ossicles
gave rise to CFU-F colonies that could be cultured, thus demon-
strating self-renewal ability in vivo and rendering CD146-labeled
uncultured cells the first specific MSC population where an
in situ counterpart has been identified and has been rigorously
tested for self-renewal potential in vivo (Sacchetti et al., 2007).
Subsequently, it was shown that in the human BM, CD271
exclusively enriches for CFU-Fs that demonstrated trilineage dif-
ferentiation potential in vitro and stains bone-lining cells in the
trabecular region and perivascular cells in the marrow. Both sin-
gle-labeled andCD271+/CD146+ dual-labeled populations were
capable of serial xenogenic transplantation (Tormin et al., 2011).
Other reports indicate that CD271 in combination with Thy1
and VCAM-1 (also known as CD90 and CD106, respectively)
enrich for clonogenic cells as demonstrated by in-vitro-limiting
dilution and single-cell culture assays. Moreover, uncultured
CD271+Thy1+ were detected in the BM of immunocompro-
mised mice upon transplantation and retained their colony for-
mation and trilineage differentiation ability in vitro (Mabuchi
et al., 2013). Other combinations such as CD146 and CD105
(Isern et al., 2013) or Integrin aV and PDGF Receptor a (PDGFRa)
(also known as CD51 and CD140a, respectively) (Pinho et al.,
2013) have been demonstrated to highly enrich for clonogenic
cells in the human BM, as demonstrated by sphere formation
assay and the ability to support primitive hematopoietic cells
in vitro. These latter two antibody combinations were originally
found to label BM Nestin-GFP+ cells in mice, which have been
shown to be multipotent and self-renewing MSCs (Me´ndez-Fer-
rer et al., 2010). It is important to mention that the CD51/CD140a
study was in fetal human BM, and the same combination does
not yield cells from adult BM (Pinho et al., 2013). Moreover, a
recent report demonstrated that CD140a-negative but not -pos-
itive cells enrich for colony forming cells in adult human BM (Li
et al., 2014)
Several other cell surfacemarkers have been used to prospec-
tively isolate human BM MSCs, including CD105, STRO-1,
SSEA-4, CD73, and CD49a, which have not been as extensively
investigated as CD271 and CD146 (Aslan et al., 2006; Boiret
et al., 2005; Gang et al., 2007; Gronthos et al., 2007; Simmons
and Torok-Storb, 1991).
Fewer studies have tested prospective isolation of murine
MSCs through the use of cell surface markers, but in a seriesof publications, the Matsuzaki group first demonstrated that
the adult murine BM contains two distinct stem cell populations
contributing to the hematopoietic and mesenchymal lineages
(Koide et al., 2007). They subsequently showed that the combi-
nation of the PDGFRa and Sca-1 in the non-hematopoietic
compartment labels a population that is enriched for CFU-F cells
in the adult murine BM. This population met the criteria of in vitro
trilineage differentiation whether after expansion or at the clonal
level when cultured in differentiationmedia directly after cell sort-
ing (Morikawa et al., 2009a, 2009b). Cells labeled with either
PDGFRa or Sca-1 demonstrated amore restricted differentiation
capability. Interestingly, the PDGFRa/Sca-1 double-negative
non-hematopoietic cells showed a higher ability to differentiate
into the osteogenic lineages when compared to the double-pos-
itive cells, indicating that these are more committed progenitors
with a restricted differentiation capability. The self-renewal ca-
pacity of these populations was investigated through non-clonal
sphere formation assays and transplantation experiments that
showed the ability of the double-positive population to repopu-
late the hematopoietic niche in vivo. Of particular interest, the
double-positive population was capable of angiogenic and neu-
ral crest differentiation as well (Morikawa et al., 2009a, 2009b).
In parallel, and in an attempt to identify the minimal required
constituents to establish a hematopoietic niche, CD105 was
found to label a primitive lineage-restricted progenitor popula-
tion that has the ability to self-renew and to transfer the hemato-
poietic microenvironment when transplanted under the kidney
capsule of adult mice. These cells were isolated from fetal,
neonatal, and adult mouse BM (Chan et al., 2009, 2013). Simi-
larly, CD105 was found to label Nestin-GFP+ enzymatically
treated BM MSCs and to enrich for mesensphere-forming cells
that demonstrated robust trilineage differentiation in vitro (Isern
et al., 2013). Independently, Pinho et al. (2013) reported the com-
bination of CD51 and PDGFRa to prospectively isolate the same
population of cells, which demonstrated a similar MSC in addi-
tion to HSC niche qualities.
Leptin Receptor (LepR) is widely expressed and labels a pop-
ulation of perivascular cells that is a major source of stem cell
factor (SCF) (Ding et al., 2012) and CXCL12 (Ding and Morrison,
2013) in BM. While originally thought to be limited in their differ-
entiation potential, these cells have now been shown to produce
osteoblasts, chondrocytes, and adipocytes in vivo (Mizoguchi
et al., 2014; Zhou et al., 2014). They overlap with CD51- and
PDGFRa-staining cells (Zhou et al., 2014), markers previously
described to label multipotent MSCs (Morikawa et al., 2009a,
2009b; Pinho et al., 2013), PDGFRb, CXCL12 Abundant Reticular
(CAR) cells (Omatsu et al., 2010), and Prx1-cre-labeled cells.
Paired related homeobox 1 (PRX1) is a transcription coactivator
that is expressed during early limb bud mesoderm development
(Logan et al., 2002). A more limited overlap was noted with Sca-
1- andCD105-labeled cells. Only a low level of Nestin expression
was noted in LepR+ cells, and there was no overlap with peri-
arteriolar NG2+ cells recently described to brightly express the
Nestin-GFP transgene and to maintain HSC quiescence (Kuni-
saki et al., 2013).
Prospective Isolation of MSCs Using Genetically
Engineered Mice
The use of genetically engineered animals had amajor impact on
the field of MSC biology. Labeling of the different mesenchymalCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 241
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specific ablation experiments possible, shedding light on the
developmental origin and the relative contribution of the different
populations to tissue homeostasis and regeneration. Animals
with reporters or cre recombinase expression under the control
of the regulatory elements of genes known to be essential in
regulating skeletal and chondrogenic development or that
show a specific expression in mesenchymal lineages have
been used (see Table 1).
Chemokine (C-X-Cmotif) ligand 12 (CXCL12), a chemo attrac-
tant and the ligand for the Chemokine (C-X-C motif) Receptor 4
(CXCR4), has been shown to be important in hematopoiesis both
at the primitive and more mature levels (Nagasawa et al., 1996;
Sugiyama et al., 2006; Zou et al., 1998). In a CXCL12-GFP
knockin mouse, reticular cells within the intra-trabecular space
of the BM showed the strongest expression of GFP, and hence,
they were namedCXCL12 Abundant Reticular (CAR) cells. Endo-
thelial cells and osteoblasts lining the endosteal surface showed
much lower or undetectable levels of GFP expression (Sugiyama
et al., 2006). Further characterization of CAR cells demonstrated
that they are also major producers of SCF in addition to being
labeled with cell surface molecules that are conventional MSC
markers, such as VCAM1, CD44, CD51, PDGFRa, and PDGFRb.
Gene expression analysis demonstrated higher levels of expres-
sion of genes that are necessary in adipogenesis and in early os-
teogenesis, and the cells demonstrated the ability of oste-adipo-
genic differentiation both in vitro and in vivo (Omatsu et al., 2010).
The Nestin-GFP transgenic mouse that expresses GFP under
the control of the 1.8 kb fragment of the Nestin gene that con-
tains the second intron (Mignone et al., 2004) was the first to
be rigorously investigated for the labeling of BM multipotent
mesenchymal stromal cells in mice (Me´ndez-Ferrer et al.,
2010). In the BM, Nestin-GFP labeled rare non-hematopoietic
stromal cells with a perivascular distribution. In the enzymatically
digested BM, Nestin-GFP+ cells were clonogenic and demon-
strated the ability to form mesenspheres and a robust self-
renewal capacity reflected by in vivo serial transplantation.
These cells were also multipotent and were able to differentiate
into the osteogenic, chondrogenic, and adipogenic lineages
in vitro. Lineage tracing using genetically engineered mice that
express the Cre recombinase under the control of the 1.8 kb
fragment of the Nestin gene, which contains the second intron
in combination with reporter mice, demonstrated the contribu-
tion of Nestin cells to osteochondral tissue remodeling (Me´n-
dez-Ferrer et al., 2010). Subsequently, the same group demon-
strated two distinct populations within the Nestin-GFP-labeled
cells. Nestin-GFP bright were rare, localized exclusively around
arterioles, and contained most of the CFU-F activity. They
were also quiescent when compared to the Nestin-GFP dim
cells, which were more abundant, reticular in shape, and mostly
associated with sinusoids (Kunisaki et al., 2013). Whereas the
Nestin-dim highly overlapped with the LepR-labeled cells, the
Nestin-GFP bright showed no LepR labeling but were positive
for NG2, which is a known pericyte marker (Kunisaki et al., 2013).
In an elegant series of temporal lineage-tracing experiments,
the Kronenberg group showed that the Nestin-GFP cells
descend from cells that express collagen II (ColII) that is known
to be expressed by chondrocytes and chondro-progenitors,
hence making it a potential marker of multipotent MSCs (Maes242 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.et al., 2010; Ono et al., 2014a). In addition, they showed that
Nestin-GFP and the Nestin-CreERT2 (Balordi and Fishell, 2007)
transgenic lines label endothelial cells in addition to mesen-
chymal cells with the latter labeling more endothelial cells (Ding
et al., 2012; Ono et al., 2014a).
TheNestin-GFP+ transgenewas also found to overlap with the
Mx-1Cre-recombinase-labeled cells (Ku¨hn et al., 1995), which in
addition to robustly labeling the hematopoietic cells, labels a
population of non-hematopoietic, non-endothelial osteogenic
cells in the bone (Park et al., 2012). Mx-1-labeled cells also over-
lapped with other MSC markers such as CD140a, CD105, and
Sca-1; was enriched in CFU-F activity; and demonstrated a clo-
nogenic trilineage differentiation ability in vitro and transplant-
ability in vivo. In addition, the Mx1-Cre transgene also labeled
more mature osterix-, osteopontin-, and osteocalcin-expressing
cells. Excluding those cells is complex, but Mx-1 single positive
labeling does help discriminate long-term osteogenic cells
among bone-forming cells. Moreover, these cells contributed
to the repair of fracture injury when endogenous or when trans-
planted (Park et al., 2012).
Paired related homeobox 1 (PRX1) is a transcription coactiva-
tor that is expressed in most cells derived from the lateral plate
mesoderm with an essential role in skeletal development (Logan
et al., 2002; Martin et al., 1995). The Prx1-Cre transgene has
been recently found to label multipotent mesenchymal progeni-
tors that partially overlaps with the PDGFRa- and Sca1- (PaS)
labeled cells and that contains all the CFU-F activity within this
population with osteogenic and adipogenic in vitro differentiation
potential. Interestingly, this population showed no expression of
Nestin, CD146, or LepR by gene expression profiling (Green-
baum et al., 2013). It is possible though that the Prx1-Cre in
this case failed to trace all PRX1-expressing cells.
Osterix (OSX) is a transcription factor that is expressed by pre-
cursors that first appear in the perichondrium and invade primary
ossification centers in parallel with blood vessels to give rise
to mature bone cells (Maes et al., 2010; Nakashima et al.,
2002). Until recently, OSX-expressing cells were thought to be
committed progenitors that transiently contribute to bone re-
modeling at least in adult mice (Park et al., 2012). However, peri-
natal OSX+ cells appear to contain MSCs that demonstrated
high CFU-F activity in addition to the ability of trilineage differen-
tiation in vitro (Mizoguchi et al., 2014). Interestingly, acutely
labeled OSX+ cells didn’t overlap with either Nestin-GFP or
LepR cells. However, after several weeks, OSX cells highly over-
lapped withNestin-GFP- and LepR-labeled populations, consis-
tent with the possibility that neonatal Osx-Cre-ERT2-labeled
cells are precursors of LepR and Nestin-GFP cells in the adult
marrow (Liu et al., 2013; Mizoguchi et al., 2014; Ono et al.,
2014a). Osterix+ cells also contribute to osteogenic, adipogenic,
and chondrogenic lineages upon injury in vivo (Mizoguchi et al.,
2014). This population is a highly potent progenitor of multiline-
age capability in the post-natal period. Similar capabilities do
not seem to accompany adult OSX+ cells, which are rare and
of limited capability.
Most recently, the bone morphogenetic protein (BMP) antag-
onist Gremlin1 (Grem1)(Hsu et al., 1998) was shown to define a
non Nestin-GFP-expressing, self-renewing population with a
restricted ability to differentiate into osteoblasts, chondrocytes,
and reticular marrow stromal cells, but not adipocytes. This
Table 1. Genetic murine models of adult BM MSCs
Marker Method of labeling
Overlap with
endogenous
markers
Overlap with genetically
labeled populations
Contribution to mesenchymal
tissues and injury repair Spatial distribution Age Reference
LepR Antibody SCF in sinusoids,
PDGFRa
LepR-Cre; Prx1-Cre Perivascular (Sinusoids(VE-
Cadherin) and arterioles(VE-
Cadherin,SM22))
2 months;
2–4 months
Zhou et al., 2014; Ding and
Morrison, 2013
LepR-Cre LepR, PDGFRb,
CD51, CD105,
PDGFRa
Cxcl12-DSred;
Nestin-GFP dim
Bone and Adipocytes
Irradiation: Osteoblasts and
adipocytes; Fracture:
Osteoblasts and osteocytes;
Perforated cartilage:
chondrocytes
Ding et al., 2012; Zhou et al.,
2014; Mizoguchi et al., 2014
LepR-Cre Osteocalcin, Dentin
Matrix Protein 1
BM cavity, cortical, and
trabecular bone
15 weeks Mizoguchi et al., 2014
OSX Osx-EGFPCre;
Osx-Cre-ERt2
VCAM1, a-SMA2,
Neurofilament M
Transient source of bone 2 months Liu et al., 2013; Park et al.,
2012
Osx-Cherry Bsp-Topaz Growth plate 8 weeks;
12 weeks
Strecker et al., 2013
Antibody Osteocytes, Cortical and
trabecular osteoblasts, and
hypertrophic chondrocytes
Strecker et al., 2013
Nestin Nestin-GFP dim LepR-Cre Associated with Sinusoids Kunisaki et al., 2013
Nestin-GFP bright NG2, a-SMA NG2-CreER Exclusively along arterioles Kunisaki et al., 2013
Nestin-GFP PDGFRa Wnt1-Cre2 4 weeks Isern et al., 2014
Nestin-CreERt2 Osteoblasts, Osteocytes,
and chondrocytes
Me´ndez-Ferrer et al., 2010
Mx1 Mx1-Cre Osteocalcin,
Osteopontin,
Osterix, CD105,
PDGFRa
Ocn-Topaz Long-term source of bone;
Fracture: Osteoblasts
Park et al., 2012
CXCL12 Cxcl12-DsRed MECA32
(Endothelial);
PDGFRa
Scf-GFP; Col1-GFP;
LepR-Cre
Ding and Morrison, 2013
Prx1 Prx1-Cre PDGFRa; Sca1
GREM1 Grem1-CreERT CD105; Low
levels of PDGFRa
and Sca1
Acta2-RFP Chondrocytes, articular
cartilage, reticular marrow
stromal cells, periosteal
cells, diaphyseal
osteoblasts, and osteocytes.
Contributes to Col1-GFP
osteoblasts and Sox9
chondrocytes in the fracture
callus
Adjacent to the growth plate
and trabecular bone
Worthley et al., 2015
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Reviewwas shown at the clonal level both in vitro and through genetic
clonal tracing in vivo (Worthley et al., 2015). An independent
group reached similar conclusions by showing that bone, carti-
lage, and stromal tissues are clonally derived using a genetic
tracingmodel in vivo (Chan et al., 2015). They defined subgroups
of cells based on immunophenotype that had different functions
upon transplantation. A hierarchy was demonstrated with (Alpha
V+Thy-6C3-CD105-CD200+) defined cells functioning asmouse
skeletal stem cell by clonal assessment of generation of seven
other subpopulations in vivo. Interestingly, single mSSC cells en-
grafted only when co-transplanted with unsorted bone cells,
suggesting a need for a supportive microenvironment. Further,
it was shown that mesenchymal lineage commitment is not rigid
in vivo and can bemodulated based on external cues dictated by
injury or disease. These findings hold major promise for clinical
settings where bone repair, cartilage regeneration, and patho-
logic ectopic bone formation remain an unmet need.
The use of cell surface markers and reporter mice has signif-
icantly impacted our understanding of MSCs in the past 5 years.
In parallel, it also provided us with valuable tools to better un-
derstand the cellular architecture and hierarchy within the he-
matopoietic niche. However, using candidate genes or antigens
to define cells has inherent biases and limitations (reviewed in
Me´ndez-Ferrer et al., 2015). Moreover, despite the advances
made in the field through the use of genetically modified ani-
mals, our understanding of the biology of the different MSC
populations in the human BM remains poor and under investi-
gated. Our recently acquired knowledge in murine models is
only valuable to use as a bridge toward a better understanding
of the human BM MSC populations given their popular use in
clinical trials for both their regenerative and immunomodulatory
characteristics (Sharma et al., 2014; Wang et al., 2014) How the
populations studied overlap or distinguish themselves is an
ongoing unmet need in the field, and a more unbiased, compre-
hensive analysis of mesenchymal cells contributing to BM
function would add greatly to our ability to understand it as a
tissue.
Mesenchymal Cells in the Hematopoietic Niche
Hematopoietic stem cells replenish hundreds of billions of blood
cells daily while maintaining themselves over decades of life
through a carefully orchestrated set of intrinsic and extrinsic
processes (reviewed in Doulatov et al., 2012; Warr et al., 2011).
The hematopoietic microenvironment, or the niche, provides
means whereby organismal needs are communicated to HSCs
(reviewed in Morrison and Scadden, 2014).
The first mesenchymal populations to be assigned niche
qualities in adult mammals were osteoblastic cells. Early studies
had demonstrated that primitive hematopoietic cells are not
randomly distributed in the BMbut reside closer to the endosteal
surface (Gong, 1978; Lord et al., 1975), and in vitro support of
hematopoiesis was facilitated by osteoblastic cells producing
cytokines (Taichman et al., 2001; Taichman and Emerson,
1994; Taichman et al., 1997). However, it was not until mesen-
chymal subpopulations were modified in vivo and hematopoietic
function was shown to be altered that the concept of a niche
(Schofield, 1978) achieved experimental definition in mammals.
Two studies demonstrated this concurrently. One modified a
specific set of osteolineage cells using a constitutively active
parathyroid hormone receptor (PTHR) and observed an increase244 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.in osteoblastic cells along with an increase in primitive hemato-
poietic cells (Calvi et al., 2003). The other study modified Mx-
1-inducible cells (subsequently shown to be osteolineage cells,
as described above) by deletion of the BMP receptor 1A and
noted a parallel increase in osteoblastic cells and primitive
hematopoietic cells (Zhang et al., 2003). The studies pre-dated
current HSC assays and do not exclude an indirect effect, but
they did demonstrate that osteolineage mesenchymal cells
contribute to the regulation of primitive hematopoietic cells.
Multiple studies have modified and refined our understanding
of which mesenchymal cells acting in particular locations partic-
ipate in HSC regulation.
It is important to note that studies done under homeostatic
conditions have yielded different results than those studying
the post-transplant setting. This is likely to be due to the effects
of cytotoxic conditioning that precede transplantation. In partic-
ular, radiation therapy dramatically and acutely affects vascular
integrity and, likely with it, the integrity of the perivascular cells.
The results are no less valid as this is a setting of high clinical
importance, but caution should be used when considering which
setting was evaluated: homeostasis or the extreme stress of
transplantation.
Initial studies of HSPC in live animals indicated that cells in-
jected into non-irradiated recipients localized to perivascular re-
gions where they could still be detected after 70 days (Sipkins
et al., 2005). The labeled cells had increased in number, suggest-
ing that HSPC persist and produce daughter cells in a perivascu-
lar setting. Subsequently, in situ HSPCwere also found to be in a
perivascular position on bone sections (Kiel et al., 2005; Nom-
bela-Arrieta et al., 2013; Sugiyama et al., 2006). In live trans-
planted animals, HSPCs were noted to accumulate closer to
endosteal surfaces (Lo Celso et al., 2009; Xie et al., 2009). This
was also the predominant position of human HSPC (Guezguez
et al., 2013). The arterioles penetrating bone are most prominent
in the periendosteal region and are also the most radiation resis-
tant. It is likely, therefore, that the close association of HSPCs
with the endosteal surface is a reflection of their proximity to spe-
cial subtypes of vasculature (Kunisaki et al., 2013). It may also be
that the osteolineage cells of the endosteal surface affect the
perivascular cells, providing indirect mechanisms of HSPC
regulation. This appears to be the case for HSPC mobilization,
for example, where depletion of mature osteoblasts leads to
impaired G-CSF mobilization (Ferraro et al., 2011). It is also
supported by data where deletion of OSX in postnatal animals
prevented osteolineage differentiation and, with it, the loss of
hematopoiesis in BM (Zhou et al., 2010). These data are rather
striking in that osteolineage-committed progenitors appear to
be critical for maintaining hematopoiesis. They suggest a critical
role for the osteolineage even under homeostatic conditions, not
just under conditions of stress like stem cell transplantation.
Some studies have also indicated that a subset of osteoblastic
cells expressing N-cadherin are rare, but may provide regulatory
cues directly to HSPC, including non-canonical Wnt signals
(Sugimura et al., 2012).
However, evidence against a direct role for osteoblastic cells
on HSPC is now considerable. It includes studies where osteo-
blastic promoters driving key regulatory genes for HSPC like
Scf or Cxcl12 did not alter HSPC number or function and where
deletion of osteoblastic cells did not markedly change HSPC
Table 2. Alterations in BM Mesenchymal Population Size and Its Effect on Hematopoeisis
Population Model Hematopoietic phenotype Reference
Osteoblastic cells Activated PTH/PTHrP
using Col1a1 2.3KbCre
line (Increased)
Immunohenotypic increase in Lin-c-Kit+Sca+ (LKS);
Increase in the frequency of primitive HSCs by LTC-IC;
Increased HSCs by competitive reconstitution
Calvi et al., 2003
Osteolineage stem cells
and osteblastic cells
Inactivation of BMPRIA
using the Mx1-Cre
(Increased)
Immunophenotypic increase in LKS; increase in LT-HSC
by BrdU labeling; increased HSCs by competetive
reconstitution
Zhang et al., 2003
Osteoblastic cells Col2.3D-TK (Depletion) 8 days: reduced B lymphopoeisis Visnjic et al., 2004
Osteoblastic cells Col2.3D-TK (Depletion) 25 days: loss of BM cellularity, immunophenotypic
reduction in B lymphopoeisis, immunophenotypic
reduction in erythroid progenitors, extramedullary
hematopoeisis, immunophenotypic reduction in myeloid
progenitors, and immunophenotypic reduction in LKS
Visnjic et al., 2004
Osteoblastic cells Col2.3D-TK (Depletion) 8 days: immunophenotypic depletion of B lymphocyte
subsets mainly pre-proB and proB; immunophenotypic
reduction in myeloid progenitors, mature monocytes,
and granulocytes.
Zhu et al., 2007
Osteoblastic cells Col2.3D-TK (Depletion) 21 days: Depletion of immunophenotypic LKS Zhu et al., 2007
Osteoblastic cells Col2.3D-TK (Depletion) 28 days: eepletion of B lymphocyte subsets and
depletion of LKS
Zhu et al., 2007
Osteoblastic cells Biglycan-deficient mice No phenotype Kiel et al., 2007
Osteoprogenitors GaS deficiency using
OsxCre::GFP line
(Depletion)
Immunophenotypic reduction in B lymphooeisis;
increased granulocytes
Wu et al., 2008
Osteoprogenitors* Osterix deficiency
(Depletion)
Decrease in LT-HSC function in the BM demonstrated
by engraftment failure due to a homing defect paralleled
with an increase in fetal liver engrafting LT-HSC
Cosxkun et al., 2014
CAR cells Cxcl1212-DTR-EGFP
line (Depletion)
Reduced BM cellularity; immunophenotypic reduction
in Common Lymphoid Progenitors (CLP) and
Megakaryocyte erythroid progenitors (MEP);
immunophenotypic and functional reduction in LT-HSC
based on competitive repopulation assay
Omatsu et al., 2010
Nestin cells DTR expression using
Nestin-CreERT2 line
2 weeks: immunophenotypic LTC-IC reduction of LT-HSC
in the BM and increase in the spleen; homing defect
Me´ndez-Ferrer et al., 2010
Nestin cells* DTR expression using
Nestin-CreERT2 line
Reduction in BM HSC activity and increase in the fetal liver
reflected by LTC-IC assays
Isern et al., 2014
*During development.
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Rather, it appears that more immature osteolineage cells are
HSPC regulators. Immature osteolineage cells include multipo-
tential stromal cells and are often in a perivascular position
(Ding and Morrison, 2013; Ding et al., 2012; Me´ndez-Ferrer
et al., 2010; Park et al., 2012; Saez et al., 2014).
The role for more immature mesenchymal progenitor or stem
cells has been documented by multiple studies. The first evi-
dence came from the laboratory of Paul Frenette where it
was shown that Nestin-GFP cells were perivascular in the BM,
were adjacent to HSPCs, and expressed high levels of HSPC
maintenance genes, and their deletion using Nestin-Cre and
Nestin-CreER reduced HSPC frequency (Me´ndez-Ferrer et al.,
2010). The Nestin-GFP cells were capable of providing bone
and other mesenchymal lineage cells in vitro and in vivo, consis-
tent with their being a mesenchymal stem cell (Me´ndez-Ferrer
et al., 2010).
Other studies have used different markers such as LepR
expression to define primitive mesenchymal cells in the adultmurine marrow, and these do have multi-potent, durable repo-
pulating ability in vivo (Zhou et al., 2014). The evidence for these
serving as hematopoietic niche cells is now extensive from the
laboratory of Sean Morrison. It includes the demonstration that
the majority of marrow stromal cells expressing SCF or
CXCL12 express LepR, and deleting those genes using a LepR
driven Cre recombinase depleted HSPC (Ding and Morrison,
2013; Ding et al., 2012). The studies were not done using induc-
ible Cre, so the deletions occurred in all LepR-expressing cells
and their descendants. The effects may have provoked multiple
compensatory pathways in development as well, so the results
should be interpreted with those caveats in mind. However,
the results showed a loss of HSPC in the BM of animals when
either Cxcl12 or scf were deleted, and similar effects were not
seen when the authors deleted the same genes in more mature
osteoblastic cells or Nestin-Cre cells. This could be due to the
broad-based effect of deleting CXCL12 or SCF from a heteroge-
neous and LepR-expressing population that encompasses the
majority of the BM stromal cells (Zhou et al., 2014).Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 245
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were conducted in Daniel Link’s laboratory. They demonstrated
that deleting CXCL12 in PRX1-labeled cells resulted in a loss in
the long-term repopulation ability of HSCs (Greenbaum et al.,
2013). PRX1 expression is required for limb development, and
labeled cells in a Prx1-cre mouse were shown to highly enrich
for CFU-F activity with the ability to differentiate into osteoblasts
and adipocytes in vitro (Greenbaum et al., 2013; Logan et al.,
2002). These data again argue for early mesenchymal cells
providing key regulatory roles for HSPC, serving as hematopoi-
etic niche participants.
Another population of well-defined mesenchymal cells ex-
press CXCL12 is a so-called CXCL12 Abundant Reticular Cell
(CAR) defined using a Cxcl12-GFP knockin animal (Sugiyama
et al., 2006). The majority of these cells express LepR (Zhou
et al., 2014), and depletion of the cells also depleted quiescent
HSPC (Omatsu et al., 2010).
It is not clear precisely how the mesenchymal populations
defined by these promoter constructs relate to one another, so
the field still requires considerable work to clarify whether MSC
subpopulations have distinctive identities and functions in
HSPC regulation. One apparent difference between Nestin-ex-
pressing and either LepR- or PRX1-expressing cells is that dele-
tion of Cxcl12 or Scf in Nestin-Cre and Nestin-CreERT2 mice
did not affect HSPCs, despite the perivascular and perisinusoi-
dal distribution of Nestin-GFP cells and their high expression of
HSC maintenance genes (Ding and Morrison, 2013; Ding et al.,
2012; Me´ndez-Ferrer et al., 2010) This was later attributed
to the fact that Nestin-Cre lines do not faithfully recapitulate
Nestin-GFP expression (Ding et al., 2012; Ono et al., 2014a). It
should also be said that it is not clear that there was efficient
deletion of the Scf or Cxcl12 genes in Nestin-expressing cells
in some of the experiments (Ding and Morrison, 2013; Ding
et al., 2012). Further clarification is needed as to the distinction
between Nestin- and LepR-expressing cells.
By introducing genetic changes in some of the mesenchymal
populations, distinctive roles are potentially revealed. This was
done with deletion of the RNA processing enzyme Dicer1.
When mature osteoblastic cells bore the deletion, there was
no apparent hematopoietic phenotype. In contrast, a plethora
of hematologic abnormalities resembling myelodysplasia was
observed when more immature OSX-expressing cells had
Dicer1 deleted (Raaijmakers et al., 2010). Importantly, a small
number of animals progressed to full blown acute myeloid leuke-
mia in this setting, suggesting the potential for a perturbed
microenvironment to be a driving force in development of malig-
nancy. In this case, it also pointed to mesenchymal cell type
specificity in affecting hematopoiesis: only the more immature
OSX driven genetic abnormality resulted in disease. Immature
mesenchymal cells appear to be the key participants in normal
HSPC regulation and in preserving the integrity of hematopoietic
tissue.
The perivascular location of MSCs raises the issue of whether
their effects are in part mediated by their interaction with endo-
thelial cells. Multiple studies have indicated HSPC niche function
for BM endothelial cells (reviewed in Doan and Chute, 2012),
including using endothelial-selective expression of Cre recombi-
nase to delete SCF or CXCL12 (Ding and Morrison, 2013; Ding
et al., 2012; Greenbaum et al., 2013). The close proximity of246 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.HSPC, MSC, and arteriolar or sinusoidal endothelium suggests
that these may provide an interactive unit for hematopoietic
regulation (Kiel et al., 2005; Kunisaki et al., 2013; Nombela-
Arrieta et al., 2013; Sugiyama et al., 2006). Those in closer prox-
imity to the endosteum and the osteolineage cells associated
with it may have a particular role in the setting of engraftment
in transplantation and perhaps in maintaining the quiescent pop-
ulation of LT-HSC (Lo Celso et al., 2009; Xie et al., 2009). Indeed,
a recent study elegantly demonstrates the coupling of angiogen-
esis and osteogenesis in the murine skeletal system where a
subpopulation of endothelial cells in the BM characterized by
strong endomucin staining provided niche signals for perivascu-
lar osteoprogenitors. Interestingly, the decline of these specific
endothelial cells was accompanied by a concomitant reduction
in osteoprogenitor cells in aged animals and their expansion
resulted in the expansion of the metaphysis and increased
formation of trabecular bone (Kusumbe et al., 2014).
Mesenchymal Cells in the Developmental
Hematopoietic Niche
Multiple waves of blood cells emerge sequentially in different
sites during the development of the hematopoietic system in ver-
tebrates. Primitive hematopoiesis is initiated by the emergence
of nucleated mature red blood cells (RBCs) and macrophages
in the extra-embryonic yolk sac. Subsequently, the earliest
definitive hematopoiesis cells appear in the area surrounding
the dorsal aorta named aorta-gonad-mesonephros (AGM), the
placenta, fetal liver, and spleen (reviewed Babovic and Eaves,
2014; Dzierzak and Speck, 2008; Orkin and Zon, 2008).
Recently, there is data supporting the existence of lymphomye-
loid immune-restricted cells (Bo¨iers et al., 2013) in addition to
engraftable multipotent progenitors (Inlay et al., 2014) even prior
to the emergence of definitive hematopoiesis.
The colonization of the BMwith long-term definitive HSCs that
persist post-natally is first detected on E17.5 and continues after
birth (Christensen et al., 2004; Wolber et al., 2002). This coin-
cides with vascular perfusion on E16.5 in mice and with the
detection of Collagen type alpha 1 (col1a1)-expressing osteo-
blasts in the periosteum of the fetal bone (Cosxkun et al., 2014).
Interestingly, HSCs in the fetal liver have different characteristics
from their counterparts in the postnatal BM. Perhaps the most
pronounced is the high proportion of cycling fetal liver HSCs,
which allows them to double every day, in contrast to adult
HSCs where the majority of cells reside in G0 (Bowie et al.,
2006; Morrison et al., 1995). Moreover, there seems to be
changes in the prevalence of lympho-deficient, balanced, and
myeloid-deficient HSCs when comparing fetal liver to fetal BM
and also when comparing these to late adult BM. Lymphoid-
balanced cells are predominant in the fetal liver, while lympho-
deficient HSCs are prevalent in the fetal BM and become
progressively more abundant with age. (Benz et al., 2012; Dyk-
stra et al., 2007).
MSCs with an in vitro ability to differentiate into osteogenic,
chondrogenic, and adipogenic lineages have been detected in
major hematopoietic sites during mouse development, such as
the AGM and fetal liver during mid-gestation and in neonatal
and adult BM (Mendes et al., 2005). Moreover, in the fetal
bone, endochondral ossification, mediated by a population of
lineage-restricted skeletal progenitors that are CD105+
Thy1.1, was found to be required for the formation of an
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HSCs (LT-HSCs). When the expression of factors involved in
endochondral ossification such asOSX and Vascular Endothelial
Growth Factor (VEGF) were suppressed, HSC niche activity
could not be detected. When the same population was isolated
from the fetal mandible or calvaria, which do not undergo endo-
chondral ossification, only bone was formed and LT-HSCs could
not be detected (Chan et al., 2009). While indicating that the
developmental capacity of mesenchymal cells is important in
their subsequent niche function, it is important to highlight the
fact that the physiology of the kidney capsule that is highly vas-
cularized does not recapitulate that of the BM, making it unclear
whether a cartilage intermediate is required. However, the devel-
opmental function that seems to be important is bone-forming
capacity. In support of this, a mouse model with Osx knockout
failed to form osteoblasts in the metaphyseal area and had
reduced LT-HSC function. BM hematopoietic cells exhibited hy-
per-proliferation, homing defects, and inability to repopulate
neonatal recipients in a transplant setting, despite normal
in vitro function and normal fetal liver hematopoietic cells (Cosx-
kun et al., 2014). Osterix-expressing cells then appear to be
important in establishing the HSC niche during development
(Cosxkun et al., 2014) as well as maintaining it in mature animals
(Zhou et al., 2010).
Osterix is critical for bone formation (Nakashima et al., 2002),
but its expression is complex and development stage depen-
dent. For example, OSX-labeled cells appear 1 day after the
perichondrium forms and coincides with the appearance of
non-endothelial Nestin-GFP-labeled cells (Mizoguchi et al.,
2014; Ono et al., 2014a). These cells contribute to nascent
bone tissue and transient stromal cells that decrease after
13 weeks. Of note, LepR-Cre-positive cells only appear on
E17.5 as a rare population and then appear to expand and
become the source of osteolineage cells at post natal stages
(Mizoguchi et al., 2014; Zhou et al., 2014). The potential for
Nestin+ or OSX+ cells being the source of LepR+ or other osteo-
lineage stem/progenitor such as MX-1+ cells is thereby raised.
Further studies are needed to clarify the hierarchical relation-
ships among these cell types in development.
In neonatal mice, OSX labeling appeared in osteoblasts, in os-
teocytes, and in cells around vessels. This labeling persisted for
up to 32 weeks. In vitro, these cells showed evidence of self-
renewal and multipotency and expressed many of the other
markers previously mentioned as indicative of a MSC population
(Nestin-GFP, LepR, PDGFRa, and PDGFRb) (Mizoguchi et al.,
2014).
However, induction of OSX+ cell labeling in more mature,
8-week-old mice labeled cells that were restricted to the bone
with no labeling of the BM stroma. Further, OSX-labeled cells
declined by 7 weeks, confirming previous data in adult mice
(Park et al., 2012). These data point to the differential activation
of the OSX promoter depending on the developmental stage of
the animal and that, in adults, OSX expression indicates an
immature cell type with a restricted differentiation potential.
The developmental origin of BMMSCs remains to be an active
area of research. Whereas it was originally believed that MSCs
are derived from the mesoderm (Dennis and Charbord, 2002),
evidence has emerged that suggests the existence of different
MSC populations in the BM during development and possiblyin the adult with distinct origins and functions (Morikawa et al.,
2009b; Nagoshi et al., 2008; Takashima et al., 2007). Most
recently, it has been shown that Nestin-GFP+ cells during peri-
natal stage exhibit HSC niche function through the secretion of
CXCL12; are descendents of the neural crest; and, unlike
mesoderm-derived MSCs, do not contribute to fetal osteochon-
drogenesis. This was shown by lineage tracing using neural-
crest-specific Wnt1-Cre2 and Sox10-CreERT2 engineered
mice in addition to diphteria toxin-mediated cell-specific
deletion experiments (Isern et al., 2014). However, reports from
other groups demonstrated a degree of overlap between Osx-
CreERT2-labeled cells and Nestin-GFP+ during fetal develop-
ment and at early post-natal stages (Mizoguchi et al., 2014;
Ono et al., 2014a). Moreover, chasing of Osx-CreERT2 cells
labeled at an early post-natal stage demonstrated a decline in
their contribution to osteoblast over time, whereas their contri-
bution to CXCL12-expressing stromal cells persisted (Ono
et al., 2014b). This raises the possibility that the expression of
certain genes such as Osterix in this case spans populations
that originate from different germ layers (see Figure 2).
In parallel, Collagen II (ColII)-labeled cells have been recently
shown by the Kronenberg group to appear earlier in the hierarchy
than Osterix; Runx2; and, interestingly, Nestin-labeled cells (Ono
et al., 2014a, 2014b). These cells when genetically labeled at an
early post-natal stage contribute to osteogenic, chondrogenic,
as well as adipogenic lineages after 1 year of lineage tracing
(Ono et al., 2014b). Interestingly, the recently described Grem1
population has been also shown to appear earlier than Nestin
and Runx2 during development and to contribute to almost all
cells of the primitive mesenchyme and primary spongiosa by
E21 (Worthley et al., 2015). The overlap between the ColII and
Grem1 population is unclear. Different methods and develop-
mental stages examined complicate direct comparisons. There-
fore, BM MSCs during development exhibit heterogeneity at the
level of gene expression pattern, origin, and function. This might
reflect distinct waves of MSCs during development similar to
what is seen when primitive gives way to definitive hematopoie-
sis (see Figure 3).
Mesenchymal Cells in Other Adult Stem Cell Niches
The last decade has witnessed an expansion of our knowledge
of adult stem cells and progenitors in tissues other than blood.
Some are similar to the HSC in maintaining tissues with a high
turnover such as the intestinal and skin (reviewed in Barker,
2014; Hsu et al., 2014; Schepeler et al., 2014). While in other tis-
sues such as skeletal muscle, stem cells known as the satellite
cells minimally contribute to myofiber maintenance during ho-
meostasis but serve an important role in regeneration after injury
(reviewed in Brack and Rando, 2012). Given the functional het-
erogeneity of the different adult stem cell populations, interest
is growing in understanding the microenvironmental cues that
contribute to their maintenance and protect them from exhaus-
tion. Similar to the HSC, adult stem cells from different tissues
reside in complex microenvironments surrounded by cells from
distinct lineages such as immune cells, epithelial cells, nerve
cells, and mesenchymal cells. Defining the subsets of these
‘‘stromal’’ cells is still to be accomplished but is likely to yield
new insights into the governance of their stem cell neighbors.
MSCs have been isolated from slowly turning over tissues
with known stem cell populations as well. For example, aCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 247
Figure 2. MSC Populations and Their Lineage-Traced Progeny during the Development of the Mouse Limb
Column 2: A schematic representation of the mouse limb and the different MSC populations through development up to 1 week after birth starting with
mesenchymal condensations and going through vascularization, formation of the mineralized matrix, and the colonization by HSCs.
Column 3: MSC populations that have been detected or traced through genetic labeling.
Column 3: The period of chase after genetic labeling.
Column 4: The progeny detected after the indicated chase time.
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with myogenic potential has been shown to play a role in muscle
regeneration after injury in vivo. These cells are enriched within248 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.the Lineage-negative, Integrin a7+, and Sca-1+ population in
the undamaged skeletal muscle and were shown to rapidly
proliferate after myotoxin-induced muscle damage and to
Figure 3. Murine MSC Ontogeny
The distinct waves of murine MSCs through
development and their contribution to bone ho-
meostasis. The blue axis represents the develop-
mental time points at which the different MSC
populations have been first detected and traced.
The red axis represents the developmental stages
at which the indicated progeny of the traced
populations has been detected.
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ferentiation. Moreover, these cells engrafted only upon trans-
plantation in muscles injected with glycerol as a model of adipo-
cytic infiltration and not in healthy muscles (Joe et al., 2010).
Thus, injury-activated mesenchymal cells may alter myogenic
populations while themselves having adipogenic, and not mus-
cle-forming, capacity. Similarly, skin-resident adipogenic pro-
genitors appear to be critical for follicular stem cell activation.
Ebf1-null mice that lack adipocyte precursors exhibit defects in
follicular stem cell activation that can be rescued with the trans-
plant of wild-type (WT) cells (Festa et al., 2011). Thus, a specific
set of adipose-forming mesenchymal cells in the dermis are crit-
ical for epithelial cell regulation in the skin.
Finally, there are a host of studies indicating that cultured
mesenchymal cells influence response to injury in a transient
and paracrine manner (Sinclair et al., 2013; Williams and Hare,
2011; Neirinckx et al., 2013; Zhu et al., 2013). The cells do not
become part of the cellular fabric of the repairing tissue, but
they are thought to contribute yet-to-be-clearly-defined cyto-
kines that modulate the injury response. These findings provide
a strong rationale to investigate the role of tissue-resident MSCs
asmodifiers of tissue response to injury in vivo in addition to their
putative niche roles.
Perspective
The MSC field has transitioned from phenomenologic begin-
nings where readily cultured cells were expanded and re-
injected in multiple disease or injury contexts to a greater
emphasis on whether MSC exist in vivo and how they function.Cell Stem CellThe latter studies depended on defining
new methods of labeling and modifying
mesenchymal cells in animal models.
The result has been a suite of indepen-
dently generated models using varying
gene promoters including Cxcl12, Osx,
Nestin, LepR, Prx1, Grem1, ColII, and
Mx-1. The lessons learned from these
indicate clear functional importance for
these cell populations in skeletal develop-
ment and repair and in the regulation of
hematopoietic tissue. However, much
work remains in defining what the rela-
tionship is between the cell types and
how they interact with each other, with
neighboring cells of endothelial or neural
origin, and how these interactive systems
interface with the hematopoietic and im-
mune cells that they regulate. The desig-
nation of ‘‘stroma’’ for everything that isnon-parenchymal in the BM or in other settings where tissue
stem cells reside has been a too easy moniker, masking the
complexity of stem cell niches and the cells that comprise
them. This has been understandable given the lack of tools to
better define the composite parts of stroma. The field has now
created the first generation of the tools needed to define func-
tionally distinct subpopulations of mesenchymal cells that
provide governance of their parenchymal neighbors. As finer res-
olution of these stromal cell types proceeds, it is likely to demon-
strate pairing with specific subtypes of parenchymal cells or to
demonstrate subsets of cells that provide quiescence or anti-
differentiative cues. In this way, it is likely that we will gain a
fine-grained understanding of the components of stroma and
their partnering parenchymal cells in BM or intestine or skin. It
will be then that we can examine the ‘‘system’’ of a tissue and
perhaps define the regulatory algorithms needed to enhance
regeneration or impair dysplasia.
It should also be noted that, while we have tried to point to
hierarchical relationships between different mesenchymal cell
populations, a model of linear transitions between cell popula-
tions sequentially emerging oversimplifies what occurs in nature.
Mesenchymal cell transitions between widely divergent cells
states, such as to and from epithelial cells (MET and EMT,
respectively) or endothelial cells, is well documented in develop-
ment and disease. Other stress conditions have revealed cells
acquiring aberrant mesenchymal cells states, such as osteo-
blastic cells in cases of heterotopic ossification after muscle
trauma. Therefore, mesenchymal cells have a plasticity and abil-
ity to respond to local signals that may defy simply lineage tree16, March 5, 2015 ª2015 Elsevier Inc. 249
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Reviewcategorization. The mesenchymal cell components of stroma
may have less rigid cell intrinsic differentiation programs and
may be more like cellular chameleons responding to the context
they are in. That will make the definition of tissue systems biology
all the more challenging, but potentially the more malleable to
therapeutic intervention.
ACKNOWLEDGMENTS
D.T.S. is Gerald and Darlene Jordan Professor of Medicine and was supported
by the National Institutes of Health (U01H100402, R01EB014703, and
R01HL044851). Y.K. is a recipient of the Aplastic Anemia and MDS Interna-
tional foundation research grant and a former recipient of the Dubai Harvard
foundation for medical research post-doctoral fellowship.
REFERENCES
Aslan, H., Zilberman, Y., Kandel, L., Liebergall, M., Oskouian, R.J., Gazit, D.,
and Gazit, Z. (2006). Osteogenic differentiation of noncultured immunoisolated
bone marrow-derived CD105+ cells. Stem Cells 24, 1728–1737.
Babovic, S., and Eaves, C.J. (2014). Hierarchical organization of fetal and adult
hematopoietic stem cells. Exp. Cell Res. 329, 185–191.
Balordi, F., and Fishell, G. (2007). Mosaic removal of hedgehog signaling in the
adult SVZ reveals that the residual wild-type stem cells have a limited capacity
for self-renewal. J. Neurosci. 27, 14248–14259.
Barker, N. (2014). Adult intestinal stem cells: critical drivers of epithelial ho-
meostasis and regeneration. Nat. Rev. Mol. Cell Biol. 15, 19–33.
Bentley, S.A., Knutsen, T., and Whang-Peng, J. (1982). The origin of the he-
matopoietic microenvironment in continuous bone marrow culture. Exp. Hem-
atol. 10, 367–372.
Benz, C., Copley, M.R., Kent, D.G., Wohrer, S., Cortes, A., Aghaeepour, N.,
Ma, E., Mader, H., Rowe, K., Day, C., et al. (2012). Hematopoietic stem cell
subtypes expand differentially during development and display distinct lym-
phopoietic programs. Cell Stem Cell 10, 273–283.
Beresford, J.N., Bennett, J.H., Devlin, C., Leboy, P.S., and Owen, M.E. (1992).
Evidence for an inverse relationship between the differentiation of adipocytic
and osteogenic cells in rat marrow stromal cell cultures. J. Cell Sci. 102,
341–351.
Bo¨iers, C., Carrelha, J., Lutteropp, M., Luc, S., Green, J.C., Azzoni, E., Woll,
P.S., Mead, A.J., Hultquist, A., Swiers, G., et al. (2013). Lymphomyeloid contri-
bution of an immune-restricted progenitor emerging prior to definitive hemato-
poietic stem cells. Cell Stem Cell 13, 535–548.
Boiret, N., Rapatel, C., Veyrat-Masson, R., Guillouard, L., Gue´rin, J.J., Pigeon,
P., Descamps, S., Boisgard, S., and Berger, M.G. (2005). Characterization of
nonexpanded mesenchymal progenitor cells from normal adult human bone
marrow. Exp. Hematol. 33, 219–225.
Boregowda, S.V., Krishnappa, V., Chambers, J.W., Lograsso, P.V., Lai, W.T.,
Ortiz, L.A., and Phinney, D.G. (2012). Atmospheric oxygen inhibits growth and
differentiation of marrow-derived mouse mesenchymal stem cells via a p53-
dependent mechanism: implications for long-term culture expansion. Stem
Cells 30, 975–987.
Bowie, M.B., McKnight, K.D., Kent, D.G., McCaffrey, L., Hoodless, P.A., and
Eaves, C.J. (2006). Hematopoietic stem cells proliferate until after birth
and show a reversible phase-specific engraftment defect. J. Clin. Invest.
116, 2808–2816.
Brack, A.S., and Rando, T.A. (2012). Tissue-specific stem cells: lessons from
the skeletal muscle satellite cell. Cell Stem Cell 10, 504–514.
Calvi, L.M., Adams, G.B., Weibrecht, K.W., Weber, J.M., Olson, D.P., Knight,
M.C., Martin, R.P., Schipani, E., Divieti, P., Bringhurst, F.R., et al. (2003).
Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425,
841–846.
Caplan, A.I. (1991). Mesenchymal stem cells. J. Orthop. Res. 9, 641–650.
Castro-Malaspina, H., Gay, R.E., Resnick, G., Kapoor, N., Meyers, P., Chiar-
ieri, D., McKenzie, S., Broxmeyer, H.E., and Moore, M.A. (1980). Characteriza-250 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.tion of human bone marrow fibroblast colony-forming cells (CFU-F) and their
progeny. Blood 56, 289–301.
Cattoretti, G., Schiro´, R., Orazi, A., Soligo, D., and Colombo, M.P. (1993). Bone
marrow stroma in humans: anti-nerve growth factor receptor antibodies selec-
tively stain reticular cells in vivo and in vitro. Blood 81, 1726–1738.
Chan, C.K., Chen, C.C., Luppen, C.A., Kim, J.B., DeBoer, A.T., Wei, K., Helms,
J.A., Kuo, C.J., Kraft, D.L., and Weissman, I.L. (2009). Endochondral ossifica-
tion is required for haematopoietic stem-cell niche formation. Nature 457,
490–494.
Chan, C.K., Lindau, P., Jiang,W., Chen, J.Y., Zhang, L.F., Chen, C.C., Seita, J.,
Sahoo, D., Kim, J.B., Lee, A., et al. (2013). Clonal precursor of bone, cartilage,
and hematopoietic niche stromal cells. Proc. Natl. Acad. Sci. USA 110, 12643–
12648.
Chan, C.K., Seo, E.Y., Chen, J.Y., Lo, D., McArdle, A., Sinha, R., Tevlin, R.,
Seita, J., Vincent-Tompkins, J., Wearda, T., et al. (2015). Identification and
specification of the mouse skeletal stem cell. Cell 160, 285–298.
Christensen, J.L., Wright, D.E., Wagers, A.J., andWeissman, I.L. (2004). Circu-
lation and chemotaxis of fetal hematopoietic stem cells. PLoS Biol. 2, E75.
Churchman, S.M., Ponchel, F., Boxall, S.A., Cuthbert, R., Kouroupis, D.,
Roshdy, T., Giannoudis, P.V., Emery, P., McGonagle, D., and Jones, E.A.
(2012). Transcriptional profile of native CD271+ multipotential stromal cells:
evidence for multiple fates, with prominent osteogenic and Wnt pathway
signaling activity. Arthritis Rheum. 64, 2632–2643.
Cosxkun, S., Chao, H., Vasavada, H., Heydari, K., Gonzales, N., Zhou, X., de
Crombrugghe, B., and Hirschi, K.K. (2014). Development of the fetal bone
marrow niche and regulation of HSC quiescence and homing ability by
emerging osteolineage cells. Cell Rep. 9, 581–590.
Dennis, J.E., and Charbord, P. (2002). Origin and differentiation of human and
murine stroma. Stem Cells 20, 205–214.
Dexter, T.M. (1982). Is the marrow stroma transplantable? Nature 298,
222–223.
Dexter, T.M., Wright, E.G., Krizsa, F., and Lajtha, L.G. (1977). Regulation of
haemopoietic stem cell proliferation in long term bone marrow cultures.
Biomedicine 27, 344–349.
Ding, L., and Morrison, S.J. (2013). Haematopoietic stem cells and early
lymphoid progenitors occupy distinct bone marrow niches. Nature 495,
231–235.
Ding, L., Saunders, T.L., Enikolopov, G., and Morrison, S.J. (2012). Endothelial
and perivascular cells maintain haematopoietic stem cells. Nature 481,
457–462.
Doan, P.L., and Chute, J.P. (2012). The vascular niche: home for normal and
malignant hematopoietic stem cells. Leukemia 26, 54–62.
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F.,
Krause, D., Deans, R., Keating, A., Prockop, Dj., and Horwitz, E. (2006). Mini-
mal criteria for defining multipotent mesenchymal stromal cells. The Interna-
tional Society for Cellular Therapy position statement. Cytotherapy 8,
315–317.
Doulatov, S., Notta, F., Laurenti, E., andDick, J.E. (2012). Hematopoiesis: a hu-
man perspective. Cell Stem Cell 10, 120–136.
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee,
S.J., Brinkman, R., and Eaves, C. (2007). Long-term propagation of distinct he-
matopoietic differentiation programs in vivo. Cell Stem Cell 1, 218–229.
Dzierzak, E., and Speck, N.A. (2008). Of lineage and legacy: the development
of mammalian hematopoietic stem cells. Nat. Immunol. 9, 129–136.
Ferraro, F., Lymperi, S., Mendez-Ferrer, S., Saez, B., Spencer, J.A., Yeap,
B.Y., Masselli, E., Graiani, G., Prezioso, L., Rizzini, E.L., et al. (2011). Diabetes
impairs hematopoietic stem cell mobilization by altering niche function. Sci
Transl Med 3, 104ra101.
Festa, E., Fretz, J., Berry, R., Schmidt, B., Rodeheffer, M., Horowitz, M., and
Horsley, V. (2011). Adipocyte lineage cells contribute to the skin stem cell niche
to drive hair cycling. Cell 146, 761–771.
Friedenstein, A. (1989). Stromal-hematopoietic interrelationships: Maximov’s
ideas and modern models. Haematol. Blood Transfus. 32, 159–167.
Cell Stem Cell
ReviewFriedenstein, A.J., Petrakova, K.V., Kurolesova, A.I., and Frolova, G.P. (1968).
Heterotopic of bonemarrow. Analysis of precursor cells for osteogenic and he-
matopoietic tissues. Transplantation 6, 230–247.
Friedenstein, A.J., Chailakhjan, R.K., and Lalykina, K.S. (1970). The develop-
ment of fibroblast colonies in monolayer cultures of guinea-pig bone marrow
and spleen cells. Cell Tissue Kinet. 3, 393–403.
Friedenstein, A.J., Gorskaja, J.F., and Kulagina, N.N. (1976). Fibroblast precur-
sors in normal and irradiated mouse hematopoietic organs. Exp. Hematol. 4,
267–274.
Friedenstein, A.J., Latzinik, N.W., Grosheva, A.G., and Gorskaya, U.F. (1982).
Marrow microenvironment transfer by heterotopic transplantation of freshly
isolated and cultured cells in porous sponges. Exp. Hematol. 10, 217–227.
Friedenstein, A.J., Chailakhyan, R.K., and Gerasimov, U.V. (1987). Bone
marrow osteogenic stem cells: in vitro cultivation and transplantation in diffu-
sion chambers. Cell Tissue Kinet. 20, 263–272.
Gang, E.J., Bosnakovski, D., Figueiredo, C.A., Visser, J.W., and Perlingeiro,
R.C. (2007). SSEA-4 identifies mesenchymal stem cells from bone marrow.
Blood 109, 1743–1751.
Gartner, S., and Kaplan, H.S. (1980). Long-term culture of human bonemarrow
cells. Proc. Natl. Acad. Sci. USA 77, 4756–4759.
Gong, J.K. (1978). Endosteal marrow: a rich source of hematopoietic stem
cells. Science 199, 1443–1445.
Greenbaum, A., Hsu, Y.M., Day, R.B., Schuettpelz, L.G., Christopher, M.J.,
Borgerding, J.N., Nagasawa, T., and Link, D.C. (2013). CXCL12 in early
mesenchymal progenitors is required for haematopoietic stem-cell mainte-
nance. Nature 495, 227–230.
Gronthos, S., Fitter, S., Diamond, P., Simmons, P.J., Itescu, S., and Zannet-
tino, A.C. (2007). A novel monoclonal antibody (STRO-3) identifies an isoform
of tissue nonspecific alkaline phosphatase expressed by multipotent bone
marrow stromal stem cells. Stem Cells Dev. 16, 953–963.
Guezguez, B., Campbell, C.J., Boyd, A.L., Karanu, F., Casado, F.L., Di Cresce,
C., Collins, T.J., Shapovalova, Z., Xenocostas, A., and Bhatia, M. (2013).
Regional localization within the bone marrow influences the functional capac-
ity of human HSCs. Cell Stem Cell 13, 175–189.
Harichandan, A., Sivasubramaniyan, K., and Bu¨hring, H.J. (2013). Prospective
isolation and characterization of human bone marrow-derived MSCs. Adv.
Biochem. Eng. Biotechnol. 129, 1–17.
Horwitz, E.M., and Keating, A. (2000). Nonhematopoietic mesenchymal stem
cells: what are they? Cytotherapy 2, 387–388.
Horwitz, E.M., Le Blanc, K., Dominici, M., Mueller, I., Slaper-Cortenbach, I.,
Marini, F.C., Deans, R.J., Krause, D.S., and Keating, A.; International Society
for Cellular Therapy (2005). Clarification of the nomenclature for MSC: The In-
ternational Society for Cellular Therapy position statement. Cytotherapy 7,
393–395.
Howlett, C.R., Cave´, J., Williamson, M., Farmer, J., Ali, S.Y., Bab, I., andOwen,
M.E. (1986). Mineralization in in vitro cultures of rabbit marrow stromal cells.
Clin. Orthop. Relat. Res. 251–263.
Hsu, D.R., Economides, A.N., Wang, X., Eimon, P.M., and Harland, R.M.
(1998). The Xenopus dorsalizing factor Gremlin identifies a novel family of
secreted proteins that antagonize BMP activities. Mol. Cell 1, 673–683.
Hsu, Y.C., Li, L., and Fuchs, E. (2014). Emerging interactions between skin
stem cells and their niches. Nat. Med. 20, 847–856.
Inlay, M.A., Serwold, T., Mosley, A., Fathman, J.W., Dimov, I.K., Seita, J., and
Weissman, I.L. (2014). Identification of multipotent progenitors that emerge
prior to hematopoietic stem cells in embryonic development. Stem Cell Rev.
2, 457–472.
Isern, J., Martı´n-Antonio, B., Ghazanfari, R., Martı´n, A.M., Lo´pez, J.A., del
Toro, R., Sa´nchez-Aguilera, A., Arranz, L., Martı´n-Pe´rez, D., Sua´rez-Lledo´,
M., et al. (2013). Self-renewing human bone marrow mesenspheres promote
hematopoietic stem cell expansion. Cell Rep. 3, 1714–1724.
Isern, J., Garcia-Garcia, A., Martin, A.M., Arranz, L., Martin-Perez, D., Torroja,
C., Sanchez-Cabo, F., and Mendez-Ferrer, S. (2014). The neural crest is a
source of mesenchymal stem cells with specialized hematopoietic stem cell
niche function. eLife 3, http://dx.doi.org/10.7554/eLife.03696.Joe, A.W., Yi, L., Natarajan, A., Le Grand, F., So, L., Wang, J., Rudnicki, M.A.,
and Rossi, F.M. (2010). Muscle injury activates resident fibro/adipogenic pro-
genitors that facilitate myogenesis. Nat. Cell Biol. 12, 153–163.
Jones, E.A., English, A., Kinsey, S.E., Straszynski, L., Emery, P., Ponchel, F.,
and McGonagle, D. (2006). Optimization of a flow cytometry-based protocol
for detection and phenotypic characterization of multipotent mesenchymal
stromal cells from human bone marrow. Cytometry B Clin. Cytom. 70,
391–399.
Jones, E., English, A., Churchman, S.M., Kouroupis, D., Boxall, S.A., Kinsey,
S., Giannoudis, P.G., Emery, P., and McGonagle, D. (2010). Large-scale
extraction and characterization of CD271+ multipotential stromal cells from
trabecular bone in health and osteoarthritis: implications for bone regeneration
strategies based on uncultured or minimally cultured multipotential stromal
cells. Arthritis Rheum. 62, 1944–1954.
Keating, A., Singer, J.W., Killen, P.D., Striker, G.E., Salo, A.C., Sanders, J.,
Thomas, E.D., Thorning, D., and Fialkow, P.J. (1982). Donor origin of the
in vitro haematopoietic microenvironment after marrow transplantation in
man. Nature 298, 280–283.
Keating, A., Powell, J., Takahashi, M., and Singer, J.W. (1984). The generation
of human long-term marrow cultures from marrow depleted of Ia (HLA-DR)
positive cells. Blood 64, 1159–1162.
Kiel, M.J., Yilmaz, O.H., Iwashita, T., Yilmaz, O.H., Terhorst, C., and Morrison,
S.J. (2005). SLAM family receptors distinguish hematopoietic stem and pro-
genitor cells and reveal endothelial niches for stem cells. Cell 121, 1109–1121.
Kiel, M.J., Radice, G.L., and Morrison, S.J. (2007). Lack of evidence that he-
matopoietic stem cells depend on N-cadherin-mediated adhesion to osteo-
blasts for their maintenance. Cell Stem Cell 1, 204–217.
Koide, Y., Morikawa, S., Mabuchi, Y., Muguruma, Y., Hiratsu, E., Hasegawa,
K., Kobayashi, M., Ando, K., Kinjo, K., Okano, H., and Matsuzaki, Y. (2007).
Two distinct stem cell lineages in murine bone marrow. Stem Cells 25,
1213–1221.
Ku¨hn, R., Schwenk, F., Aguet, M., and Rajewsky, K. (1995). Inducible gene tar-
geting in mice. Science 269, 1427–1429.
Kunisaki, Y., Bruns, I., Scheiermann, C., Ahmed, J., Pinho, S., Zhang, D., Miz-
oguchi, T., Wei, Q., Lucas, D., Ito, K., et al. (2013). Arteriolar niches maintain
haematopoietic stem cell quiescence. Nature 502, 637–643.
Kusumbe, A.P., Ramasamy, S.K., and Adams, R.H. (2014). Coupling of angio-
genesis and osteogenesis by a specific vessel subtype in bone. Nature 507,
323–328.
Kuznetsov, S.A., Krebsbach, P.H., Satomura, K., Kerr, J., Riminucci, M., Be-
nayahu, D., and Robey, P.G. (1997). Single-colony derived strains of human
marrow stromal fibroblasts form bone after transplantation in vivo. J. Bone
Miner. Res. 12, 1335–1347.
Li, H., Ghazanfari, R., Zacharaki, D., Ditzel, N., Isern, J., Ekblom, M., Me´ndez-
Ferrer, S., Kassem, M., and Scheding, S. (2014). Low/negative expression of
PDGFR-a identifies the candidate primary mesenchymal stromal cells in adult
human bone marrow. Stem Cell Rev. 3, 965–974.
Liu, Y., Strecker, S., Wang, L., Kronenberg, M.S., Wang, W., Rowe, D.W., and
Maye, P. (2013). Osterix-cre labeled progenitor cells contribute to the forma-
tion and maintenance of the bone marrow stroma. PLoS ONE 8, e71318.
Lo Celso, C., Fleming, H.E., Wu, J.W., Zhao, C.X., Miake-Lye, S., Fujisaki, J.,
Coˆte´, D., Rowe, D.W., Lin, C.P., and Scadden, D.T. (2009). Live-animal
tracking of individual haematopoietic stem/progenitor cells in their niche.
Nature 457, 92–96.
Logan, M., Martin, J.F., Nagy, A., Lobe, C., Olson, E.N., and Tabin, C.J. (2002).
Expression of Cre Recombinase in the developing mouse limb bud driven by a
Prxl enhancer. Genesis 33, 77–80.
Lord, B.I., Testa, N.G., and Hendry, J.H. (1975). The relative spatial distribu-
tions of CFUs and CFUc in the normal mouse femur. Blood 46, 65–72.
Mabuchi, Y., Morikawa, S., Harada, S., Niibe, K., Suzuki, S., Renault-Mihara,
F., Houlihan, D.D., Akazawa, C., Okano, H., and Matsuzaki, Y. (2013).
LNGFR(+)THY-1(+)VCAM-1(hi+) cells reveal functionally distinct subpopula-
tions in mesenchymal stem cells. Stem Cell Rev. 1, 152–165.
Maes, C., Kobayashi, T., Selig, M.K., Torrekens, S., Roth, S.I., Mackem, S.,
Carmeliet, G., and Kronenberg, H.M. (2010). Osteoblast precursors, but notCell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 251
Cell Stem Cell
Reviewmature osteoblasts, move into developing and fractured bones along with
invading blood vessels. Dev. Cell 19, 329–344.
Mardon, H.J., Bee, J., von der Mark, K., and Owen, M.E. (1987). Development
of osteogenic tissue in diffusion chambers from early precursor cells in bone
marrow of adult rats. Cell Tissue Res. 250, 157–165.
Martin, J.F., Bradley, A., and Olson, E.N. (1995). The paired-like homeo box
gene MHox is required for early events of skeletogenesis in multiple lineages.
Genes Dev. 9, 1237–1249.
McCulloch, E.A., and Till, J.E. (1960). The radiation sensitivity of normal mouse
bone marrow cells, determined by quantitative marrow transplantation into
irradiated mice. Radiat. Res. 13, 115–125.
Mendes, S.C., Robin, C., and Dzierzak, E. (2005). Mesenchymal progenitor
cells localize within hematopoietic sites throughout ontogeny. Development
132, 1127–1136.
Me´ndez-Ferrer, S., Michurina, T.V., Ferraro, F., Mazloom, A.R., Macarthur,
B.D., Lira, S.A., Scadden, D.T., Ma’ayan, A., Enikolopov, G.N., and Frenette,
P.S. (2010). Mesenchymal and haematopoietic stem cells form a unique
bone marrow niche. Nature 466, 829–834.
Me´ndez-Ferrer, S., Scadden, D.T., and Sa´nchez-Aguilera, A. (2015). Bone
marrow stem cells: current and emerging concepts. Ann. N Y Acad. Sci.
1335, 32–44.
Mignone, J.L., Kukekov, V., Chiang, A.S., Steindler, D., and Enikolopov, G.
(2004). Neural stem and progenitor cells in nestin-GFP transgenic mice.
J. Comp. Neurol. 469, 311–324.
Mizoguchi, T., Pinho, S., Ahmed, J., Kunisaki, Y., Hanoun, M., Mendelson, A.,
Ono, N., Kronenberg, H.M., and Frenette, P.S. (2014). Osterix marks distinct
waves of primitive and definitive stromal progenitors during bone marrow
development. Dev. Cell 29, 340–349.
Morikawa, S., Mabuchi, Y., Kubota, Y., Nagai, Y., Niibe, K., Hiratsu, E., Suzuki,
S., Miyauchi-Hara, C., Nagoshi, N., Sunabori, T., et al. (2009a). Prospective
identification, isolation, and systemic transplantation of multipotent mesen-
chymal stem cells in murine bone marrow. J. Exp. Med. 206, 2483–2496.
Morikawa, S., Mabuchi, Y., Niibe, K., Suzuki, S., Nagoshi, N., Sunabori, T.,
Shimmura, S., Nagai, Y., Nakagawa, T., Okano, H., and Matsuzaki, Y.
(2009b). Development of mesenchymal stem cells partially originate from the
neural crest. Biochem. Biophys. Res. Commun. 379, 1114–1119.
Morrison, S.J., and Scadden, D.T. (2014). The bone marrow niche for haema-
topoietic stem cells. Nature 505, 327–334.
Morrison, S.J., Hemmati, H.D., Wandycz, A.M., andWeissman, I.L. (1995). The
purification and characterization of fetal liver hematopoietic stem cells. Proc.
Natl. Acad. Sci. USA 92, 10302–10306.
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kita-
mura, Y., Yoshida, N., Kikutani, H., and Kishimoto, T. (1996). Defects of
B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the
CXC chemokine PBSF/SDF-1. Nature 382, 635–638.
Nagoshi, N., Shibata, S., Kubota, Y., Nakamura, M., Nagai, Y., Satoh, E., Mor-
ikawa, S., Okada, Y., Mabuchi, Y., Katoh, H., et al. (2008). Ontogeny andmulti-
potency of neural crest-derived stem cells in mouse bone marrow, dorsal root
ganglia, and whisker pad. Cell Stem Cell 2, 392–403.
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J.M., Behringer, R.R.,
and de Crombrugghe, B. (2002). The novel zinc finger-containing transcription
factor osterix is required for osteoblast differentiation and bone formation. Cell
108, 17–29.
Neirinckx, V., Coste, C., Rogister, B., and Wislet-Gendebien, S. (2013).
Concise review: adult mesenchymal stem cells, adult neural crest stem cells,
and therapy of neurological pathologies: a state of play. Stem Cells Transl.
Med. 2, 284–296.
Nombela-Arrieta, C., Pivarnik, G., Winkel, B., Canty, K.J., Harley, B., Mahoney,
J.E., Park, S.Y., Lu, J., Protopopov, A., and Silberstein, L.E. (2013). Quantita-
tive imaging of haematopoietic stem and progenitor cell localization and hyp-
oxic status in the bone marrow microenvironment. Nat. Cell Biol. 15, 533–543.
Omatsu, Y., Sugiyama, T., Kohara, H., Kondoh, G., Fujii, N., Kohno, K., andNa-
gasawa, T. (2010). The essential functions of adipo-osteogenic progenitors as
the hematopoietic stem and progenitor cell niche. Immunity 33, 387–399.252 Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc.Ono, N., Ono, W., Mizoguchi, T., Nagasawa, T., Frenette, P.S., and Kronen-
berg, H.M. (2014a). Vasculature-associated cells expressing nestin in devel-
oping bones encompass early cells in the osteoblast and endothelial lineage.
Dev. Cell 29, 330–339.
Ono, N., Ono, W., Nagasawa, T., and Kronenberg, H.M. (2014b). A subset of
chondrogenic cells provides early mesenchymal progenitors in growing
bones. Nat. Cell Biol. 16, 1157–1167.
Orkin, S.H., and Zon, L.I. (2008). Hematopoiesis: an evolving paradigm for
stem cell biology. Cell 132, 631–644.
Owen, M. (1963). Cell Population Kinetics of an Osteogenic Tissue. I. J. Cell
Biol. 19, 19–32.
Owen, M. (1967). Uptake of [3H] uridine into precursor pools and RNA in oste-
ogenic cells. J. Cell Sci. 2, 39–56.
Owen, M., and Friedenstein, A.J. (1988). Stromal stem cells: marrow-derived
osteogenic precursors. Ciba Found. Symp. 136, 42–60.
Owen, M., and MacPherson, S. (1963). Cell Population Kinetics of an Osteo-
genic Tissue. Ii. J. Cell Biol. 19, 33–44.
Park, D., Spencer, J.A., Koh, B.I., Kobayashi, T., Fujisaki, J., Clemens, T.L.,
Lin, C.P., Kronenberg, H.M., and Scadden, D.T. (2012). Endogenous bone
marrow MSCs are dynamic, fate-restricted participants in bone maintenance
and regeneration. Cell Stem Cell 10, 259–272.
Pinho, S., Lacombe, J., Hanoun, M., Mizoguchi, T., Bruns, I., Kunisaki, Y., and
Frenette, P.S. (2013). PDGFRa and CD51mark human nestin+ sphere-forming
mesenchymal stem cells capable of hematopoietic progenitor cell expansion.
J. Exp. Med. 210, 1351–1367.
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca,
J.D., Moorman, M.A., Simonetti, D.W., Craig, S., and Marshak, D.R. (1999).
Multilineage potential of adult human mesenchymal stem cells. Science 284,
143–147.
Prockop, D.J. (1997). Marrow stromal cells as stem cells for nonhematopoietic
tissues. Science 276, 71–74.
Qian, H., Le Blanc, K., and Sigvardsson, M. (2012). Primary mesenchymal
stem and progenitor cells from bone marrow lack expression of CD44 protein.
J. Biol. Chem. 287, 25795–25807.
Quirici, N., Soligo, D., Bossolasco, P., Servida, F., Lumini, C., and Deliliers,
G.L. (2002). Isolation of bone marrow mesenchymal stem cells by anti-nerve
growth factor receptor antibodies. Exp. Hematol. 30, 783–791.
Raaijmakers, M.H., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoon-
maker, J.A., Ebert, B.L., Al-Shahrour, F., Hasserjian, R.P., Scadden, E.O., et al.
(2010). Bone progenitor dysfunction induces myelodysplasia and secondary
leukaemia. Nature 464, 852–857.
Sacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I.,
Tagliafico, E., Ferrari, S., Robey, P.G., Riminucci, M., and Bianco, P. (2007).
Self-renewing osteoprogenitors in bone marrow sinusoids can organize a
hematopoietic microenvironment. Cell 131, 324–336.
Saez, B., Ferraro, F., Yusuf, R.Z., Cook, C.M., Yu, V.W., Pardo-Saganta, A.,
Sykes, S.M., Palchaudhuri, R., Schajnovitz, A., Lotinun, S., et al. (2014). Inhib-
iting stromal cell heparan sulfate synthesis improves stem cell mobilization and
enables engraftment without cytotoxic conditioning. Blood 124, 2937–2947.
Schepeler, T., Page, M.E., and Jensen, K.B. (2014). Heterogeneity and plas-
ticity of epidermal stem cells. Development 141, 2559–2567.
Schofield, R. (1978). The relationship between the spleen colony-forming cell
and the haemopoietic stem cell. Blood Cells 4, 7–25.
Sharma, R.R., Pollock, K., Hubel, A., and McKenna, D. (2014). Mesenchymal
stem or stromal cells: a review of clinical applications andmanufacturing prac-
tices. Transfusion 54, 1418–1437.
Siminovitch, L., McCulloch, E.A., and Till, J.E. (1963). The Distribution of Col-
ony-Forming Cells among Spleen Colonies. J. Cell. Physiol. 62, 327–336.
Simmons, P.J., and Torok-Storb, B. (1991). Identification of stromal cell pre-
cursors in human bone marrow by a novel monoclonal antibody, STRO-1.
Blood 78, 55–62.
Cell Stem Cell
ReviewSinclair, K., Yerkovich, S.T., and Chambers, D.C. (2013). Mesenchymal stem
cells and the lung. Respirology 18, 397–411.
Sipkins, D.A., Wei, X., Wu, J.W., Runnels, J.M., Coˆte´, D., Means, T.K., Luster,
A.D., Scadden, D.T., and Lin, C.P. (2005). In vivo imaging of specialized bone
marrow endothelial microdomains for tumour engraftment. Nature 435,
969–973.
Strecker, S., Fu, Y., Liu, Y., and Maye, P. (2013). Generation and characteriza-
tion of Osterix-Cherry reporter mice. Genesis 51, 246–258.
Sugimura, R., He, X.C., Venkatraman, A., Arai, F., Box, A., Semerad, C., Haug,
J.S., Peng, L., Zhong, X.B., Suda, T., and Li, L. (2012). Noncanonical Wnt
signaling maintains hematopoietic stem cells in the niche. Cell 150, 351–365.
Sugiyama, T., Kohara, H., Noda, M., and Nagasawa, T. (2006). Maintenance of
the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in
bone marrow stromal cell niches. Immunity 25, 977–988.
Taichman, R.S., and Emerson, S.G. (1994). Human osteoblasts support hema-
topoiesis through the production of granulocyte colony-stimulating factor.
J. Exp. Med. 179, 1677–1682.
Taichman, R.S., Reilly, M.J., Verma, R.S., and Emerson, S.G. (1997).
Augmented production of interleukin-6 by normal human osteoblasts in
response to CD34+ hematopoietic bone marrow cells in vitro. Blood 89,
1165–1172.
Taichman, R., Reilly, M., Verma, R., Ehrenman, K., and Emerson, S. (2001). He-
patocyte growth factor is secreted by osteoblasts and cooperatively permits
the survival of haematopoietic progenitors. Br. J. Haematol. 112, 438–448.
Takashima, Y., Era, T., Nakao, K., Kondo, S., Kasuga, M., Smith, A.G., and
Nishikawa, S. (2007). Neuroepithelial cells supply an initial transient wave of
MSC differentiation. Cell 129, 1377–1388.
Tavassoli, M., and Crosby,W.H. (1968). Transplantation of marrow to extrame-
dullary sites. Science 161, 54–56.
Thomson, T.M., Rettig, W.J., Chesa, P.G., Green, S.H., Mena, A.C., and Old,
L.J. (1988). Expression of human nerve growth factor receptor on cells derived
from all three germ layers. Exp. Cell Res. 174, 533–539.
Till, J.E., and McCulloch, E.A. (1961). A direct measurement of the radiation
sensitivity of normal mouse bone marrow cells. Radiat. Res. 14, 213–222.
Tormin, A., Li, O., Brune, J.C., Walsh, S., Schu¨tz, B., Ehinger, M., Ditzel, N.,
Kassem, M., and Scheding, S. (2011). CD146 expression on primary nonhe-
matopoietic bone marrow stem cells is correlated with in situ localization.
Blood 117, 5067–5077.
Via, A.G., Frizziero, A., and Oliva, F. (2012). Biological properties of mesen-
chymal Stem Cells from different sources. Muscles Ligaments Tendons J.
16, 154–162.
Visnjic, D., Kalajzic, Z., Rowe, D.W., Katavic, V., Lorenzo, J., and Aguila, H.L.
(2004). Hematopoiesis is severely altered in mice with an induced osteoblast
deficiency. Blood 103, 3258–3264.Wakitani, S., Saito, T., and Caplan, A.I. (1995). Myogenic cells derived from rat
bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle
Nerve 18, 1417–1426.
Wang, Y., Chen, X., Cao, W., and Shi, Y. (2014). Plasticity of mesenchymal
stem cells in immunomodulation: pathological and therapeutic implications.
Nat. Immunol. 15, 1009–1016.
Warr, M.R., Pietras, E.M., and Passegue, E. (2011). Mechanisms controlling
hematopoietic stem cell functions during normal hematopoiesis and hemato-
logical malignancies. Wiley Interdiscip. Rev. Syst. Biol. Med. 3, 681–701.
Williams, A.R., and Hare, J.M. (2011). Mesenchymal stem cells: biology, path-
ophysiology, translational findings, and therapeutic implications for cardiac
disease. Circ. Res. 109, 923–940.
Wolber, F.M., Leonard, E., Michael, S., Orschell-Traycoff, C.M., Yoder, M.C.,
and Srour, E.F. (2002). Roles of spleen and liver in development of the murine
hematopoietic system. Exp. Hematol. 30, 1010–1019.
Worthley, D.L., Churchill, M., Compton, J.T., Tailor, Y., Rao, M., Si, Y., Levin,
D., Schwartz, M.G., Uygur, A., Hayakawa, Y., et al. (2015). Gremlin 1 identifies
a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell
160, 269–284.
Wu, J.Y., Purton, L.E., Rodda, S.J., Chen, M., Weinstein, L.S., McMahon, A.P.,
Scadden, D.T., and Kronenberg, H.M. (2008). Osteoblastic regulation of B
lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways.
Proc. Natl. Acad. Sci. USA 105, 16976–16981.
Xie, Y., Yin, T., Wiegraebe, W., He, X.C., Miller, D., Stark, D., Perko, K., Alex-
ander, R., Schwartz, J., Grindley, J.C., et al. (2009). Detection of functional
haematopoietic stem cell niche using real-time imaging. Nature 457, 97–101.
Zhang, J., Niu, C., Ye, L., Huang, H., He, X., Tong, W.G., Ross, J., Haug, J.,
Johnson, T., Feng, J.Q., et al. (2003). Identification of the haematopoietic
stem cell niche and control of the niche size. Nature 425, 836–841.
Zhou, X., Zhang, Z., Feng, J.Q., Dusevich, V.M., Sinha, K., Zhang, H., Darnay,
B.G., and de Crombrugghe, B. (2010). Multiple functions of Osterix are
required for bone growth and homeostasis in postnatal mice. Proc. Natl.
Acad. Sci. USA 107, 12919–12924.
Zhou, B.O., Yue, R., Murphy, M.M., Peyer, J.G., and Morrison, S.J. (2014).
Leptin-receptor-expressing mesenchymal stromal cells represent the main
source of bone formed by adult bone marrow. Cell Stem Cell 15, 154–168.
Zhu, J., Garrett, R., Jung, Y., Zhang, Y., Kim, N., Wang, J., Joe, G.J., Hexner,
E., Choi, Y., Taichman, R.S., and Emerson, S.G. (2007). Osteoblasts support
B-lymphocyte commitment and differentiation from hematopoietic stem cells.
Blood 109, 3706–3712.
Zhu, X.Y., Lerman, A., and Lerman, L.O. (2013). Concise review: mesenchymal
stem cell treatment for ischemic kidney disease. Stem Cells 31, 1731–1736.
Zou, Y.R., Kottmann, A.H., Kuroda, M., Taniuchi, I., and Littman, D.R. (1998).
Function of the chemokine receptor CXCR4 in haematopoiesis and in cere-
bellar development. Nature 393, 595–599.Cell Stem Cell 16, March 5, 2015 ª2015 Elsevier Inc. 253
